Oramed Pharmaceuticals Inc. Stock Deutsche Boerse AG

OJU1

US68403P2039

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG Other stock markets 02:00:34 2026-06-24 EDT			5-day change	1st Jan Change
3.615 ^EUR	+4.93%		+12.62%	+49.88%

05-19	Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024.	CI

Valuation: Oramed Pharmaceuticals Inc.

Market Cap	176M 155M 143M 134M 250M 16.59B 255M 1.72B 665M 8.18B 661M 646M 28.47B	P/E 2026 *	1.86x	P/E 2027 *	-
Enterprise Value	176M 155M 143M 134M 250M 16.59B 255M 1.72B 665M 8.18B 661M 646M 28.47B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	82.16%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Chart: Oramed Pharmaceuticals Inc.

Timeframe

Style

Dynamic Chart

Latest news : Oramed Pharmaceuticals Inc.

05-19	Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024.	CI
03-26	Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-25	Lifeward Closes Oramed Partnership, Acquires Oratech Pharma	MT
03-24	Lifeward Ltd. announced that it has received $9 million in funding from Oramed Pharmaceuticals Inc.	CI
03-24	Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc..	CI
03-13	Lifeward Shareholders Approve Share Issuance for Oramed Partnership	MT
02-19	Oramed Pharmaceuticals Inc Intends to Engage Nano Dimension Ltd	CI
02-11	Lifeward Ltd. announced that it has received $0.525 million in funding	CI
01-29	Oramed Pharmaceuticals Inc Intends to Engage Nano Dimension Ltd	CI
01-13	Lifeward Obtains Investment, Protein Oral Delivery Technology From Oramed	MT
01-13	Oramed and Lifeward announce strategic transaction	RE
01-12	Lifeward Ltd. entered into a share purchase agreement to acquire Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc..	CI

More news

Analysts' recommendations: Oramed Pharmaceuticals Inc.

23-05-17	Canaccord Genuity Adjusts Price Target on Oramed Pharmaceuticals to $2 From $3, Maintains Hold Rating	MT
23-01-17	HC Wainwright Downgrades Oramed Pharmaceuticals to Neutral From Buy	MT
23-01-12	Cantor Fitzgerald Downgrades Oramed Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $5 From $20	MT
23-01-12	Canaccord Genuity Downgrades Oramed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $3 From $30	MT
22-05-16	Aegis Capital Adjusts Price Target for Oramed Pharmaceuticals to $30 From $35, Maintains Buy Rating	MT

More recommendations

Press Releases: Oramed Pharmaceuticals Inc.

06-17	Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes	PR
05-19	Oramed: Q1 Earnings Snapshot	AQ
03-26	Oramed: Q4 Earnings Snapshot	AQ
03-13	Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company	AQ
11-13	Oramed: Q3 Earnings Snapshot	AQ

More press releases

News in other languages: Oramed Pharmaceuticals Inc.

21-03-22	Premas Biotech : et Oramed annoncent un vaccin candidat oral contre la COVID-19 qui produit des anticorps après une seule dose
15-11-30	Amazon : Les valeurs à suivre sur les marchés américains
15-11-30	USA-Les valeurs à suivre à Wall Street

More news

Managers and Directors: Oramed Pharmaceuticals Inc.

Manager	Title	Age	Since
Miriam Kidron CTO	Chief Tech/Sci/R&D Officer	85	2006-02-28
Nadav Kidron CEO	Chief Executive Officer	52	2006-03-07
Avraham Gabay DFI	Director of Finance/CFO	41	2019-05-31

Director	Title	Age	Since
Nadav Kidron CHM	Chairman	52	2022-06-29
Miriam Kidron BRD	Director/Board Member	85	2002-04-11
Arie Mayer BRD	Director/Board Member	69	2019-12-04

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORAMED PHARMACEUTICALS INC.	+4.93%	+12.62%	-	-	171M
LONZA GROUP AG	+2.56%	+7.12%	-7.30%	-0.26%	44.45B
REVOLUTION MEDICINES, INC.	+0.15%	+7.61%	+324.11%	+565.24%	36.04B
BEONE MEDICINES AG	+0.36%	+5.50%	+3.87%	+54.57%	30.7B
IQVIA HOLDINGS INC.	+8.37%	+8.76%	+17.05%	-13.29%	28.59B
CELLTRION, INC.	+7.60%	-1.09%	+12.49%	+20.82%	23.01B
ASCENDIS PHARMA A/S	-0.24%	+2.97%	-	-	14.82B
MEDPACE HOLDINGS, INC.	+8.30%	+12.19%	+62.65%	+129.55%	13.52B
EUROFINS SCIENTIFIC SE	+2.73%	+7.16%	+11.00%	+18.45%	12.98B
IONIS PHARMACEUTICALS, INC.	+0.70%	+2.97%	+93.04%	+93.04%	12.56B
Average	+3.55%	+4.61%	+64.61%	+108.52%	24.07B
Weighted average by Cap.	+3.22%	+4.99%	+71.38%	+125.31%

See all sector performances

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Employees

Sector

Biotechnology & Medical Research

More about the company